You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain ...

Pop quiz: would you prefer to take a medication as a pill or inject yourself with it? Somehow, I suspect that the vast ...

Branded drug manufacturers, including Eli Lilly and Company (Eli Lilly), have been pursuing various legal actions against compounding pharmacies ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 and ...

The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

How can policy makers and health care leaders ensure affordable, equitable access to GLP-1 medications while managing their ...

Despite the $1,000-per-dose price tag, GLP-1s may offer long-term ROI by lowering chronic disease rates GLP-1 weight loss ...